vs
Emergent BioSolutions Inc.（EBS）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是Emergent BioSolutions Inc.的1.3倍（$188.3M vs $148.7M），BRC Group Holdings, Inc.净利率更高（47.9% vs -36.7%，领先84.7%），BRC Group Holdings, Inc.同比增速更快（-21.9% vs -23.6%），过去两年BRC Group Holdings, Inc.的营收复合增速更高（-15.4% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
EBS vs RILY — 直观对比
营收规模更大
RILY
是对方的1.3倍
$148.7M
营收增速更快
RILY
高出1.8%
-23.6%
净利率更高
RILY
高出84.7%
-36.7%
两年增速更快
RILY
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $188.3M |
| 净利润 | $-54.6M | $90.3M |
| 毛利率 | 42.9% | 79.5% |
| 营业利润率 | -18.8% | 32.3% |
| 净利率 | -36.7% | 47.9% |
| 营收同比 | -23.6% | -21.9% |
| 净利润同比 | -74.4% | 1710.8% |
| 每股收益（稀释后） | $-0.95 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRILY
| Q4 25 | $148.7M | $188.3M | ||
| Q3 25 | $231.1M | $215.3M | ||
| Q2 25 | $140.9M | $188.2M | ||
| Q1 25 | $222.2M | $197.2M | ||
| Q4 24 | $194.7M | $241.0M | ||
| Q3 24 | $293.8M | $225.5M | ||
| Q2 24 | $254.7M | $256.0M | ||
| Q1 24 | $300.4M | $263.4M |
净利润EBSRILY
| Q4 25 | $-54.6M | $90.3M | ||
| Q3 25 | $51.2M | $91.1M | ||
| Q2 25 | $-12.0M | $139.5M | ||
| Q1 25 | $68.0M | $-10.0M | ||
| Q4 24 | $-31.3M | $-5.6M | ||
| Q3 24 | $114.8M | $-284.4M | ||
| Q2 24 | $-283.1M | $-433.6M | ||
| Q1 24 | $9.0M | $-49.2M |
毛利率EBSRILY
| Q4 25 | 42.9% | 79.5% | ||
| Q3 25 | 62.8% | 83.7% | ||
| Q2 25 | 52.5% | 81.3% | ||
| Q1 25 | 60.2% | 81.4% | ||
| Q4 24 | 39.4% | 79.8% | ||
| Q3 24 | 54.9% | 82.1% | ||
| Q2 24 | -18.8% | 84.5% | ||
| Q1 24 | 49.2% | 85.3% |
营业利润率EBSRILY
| Q4 25 | -18.8% | 32.3% | ||
| Q3 25 | 33.1% | 30.4% | ||
| Q2 25 | 1.1% | 5.7% | ||
| Q1 25 | 22.5% | -31.2% | ||
| Q4 24 | -4.9% | -69.2% | ||
| Q3 24 | 22.0% | -36.4% | ||
| Q2 24 | -79.9% | -90.8% | ||
| Q1 24 | 13.2% | -6.1% |
净利率EBSRILY
| Q4 25 | -36.7% | 47.9% | ||
| Q3 25 | 22.2% | 42.3% | ||
| Q2 25 | -8.5% | 74.1% | ||
| Q1 25 | 30.6% | -5.1% | ||
| Q4 24 | -16.1% | -2.3% | ||
| Q3 24 | 39.1% | -126.1% | ||
| Q2 24 | -111.2% | -169.4% | ||
| Q1 24 | 3.0% | -18.7% |
每股收益（稀释后）EBSRILY
| Q4 25 | $-0.95 | $2.78 | ||
| Q3 25 | $0.91 | $2.91 | ||
| Q2 25 | $-0.22 | $4.50 | ||
| Q1 25 | $1.19 | $-0.39 | ||
| Q4 24 | $-0.45 | $-0.01 | ||
| Q3 24 | $2.06 | $-9.39 | ||
| Q2 24 | $-5.38 | $-14.35 | ||
| Q1 24 | $0.17 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $226.6M |
| 总债务越低越好 | $589.7M | $1.4B |
| 股东权益账面价值 | $522.6M | $-171.5M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSRILY
| Q4 25 | $205.4M | $226.6M | ||
| Q3 25 | $245.5M | $184.2M | ||
| Q2 25 | $267.3M | $267.4M | ||
| Q1 25 | $149.1M | $138.3M | ||
| Q4 24 | $99.5M | $146.9M | ||
| Q3 24 | $149.9M | $159.2M | ||
| Q2 24 | $69.7M | $236.9M | ||
| Q1 24 | $78.5M | $190.7M |
总债务EBSRILY
| Q4 25 | $589.7M | $1.4B | ||
| Q3 25 | $693.1M | $1.3B | ||
| Q2 25 | $700.0M | $1.3B | ||
| Q1 25 | $700.0M | $1.4B | ||
| Q4 24 | $700.0M | $1.5B | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
股东权益EBSRILY
| Q4 25 | $522.6M | $-171.5M | ||
| Q3 25 | $582.5M | $-260.5M | ||
| Q2 25 | $536.2M | $-351.7M | ||
| Q1 25 | $552.7M | $-496.8M | ||
| Q4 24 | $482.8M | $-488.2M | ||
| Q3 24 | $508.4M | $-497.6M | ||
| Q2 24 | $386.3M | $-218.3M | ||
| Q1 24 | $663.9M | $228.4M |
总资产EBSRILY
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.5B | $1.7B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.5B | $3.2B | ||
| Q1 24 | $1.8B | $5.0B |
负债/权益比EBSRILY
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | — |
| 自由现金流率自由现金流/营收 | 49.6% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $156.8M | — |
8季度趋势，按日历期对齐
经营现金流EBSRILY
| Q4 25 | $77.7M | $26.2M | ||
| Q3 25 | $-2.3M | $-60.6M | ||
| Q2 25 | $106.4M | $-25.6M | ||
| Q1 25 | $-11.2M | $184.0K | ||
| Q4 24 | $-79.9M | $-2.7M | ||
| Q3 24 | $153.7M | $19.5M | ||
| Q2 24 | $47.5M | $111.5M | ||
| Q1 24 | $-62.6M | $135.4M |
自由现金流EBSRILY
| Q4 25 | $73.8M | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $103.5M | — | ||
| Q1 25 | $-14.8M | — | ||
| Q4 24 | $-81.6M | — | ||
| Q3 24 | $147.9M | — | ||
| Q2 24 | $42.9M | — | ||
| Q1 24 | $-73.4M | — |
自由现金流率EBSRILY
| Q4 25 | 49.6% | — | ||
| Q3 25 | -2.5% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | -6.7% | — | ||
| Q4 24 | -41.9% | — | ||
| Q3 24 | 50.3% | — | ||
| Q2 24 | 16.8% | — | ||
| Q1 24 | -24.4% | — |
资本支出强度EBSRILY
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 3.6% | — |
现金转化率EBSRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | -0.04× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
